© Drug Hunter Inc. 2018-2023
Home > CG428
CRBN-based TRK kinase fusion prot. degrader
degrad. of mult. TRK fusions (e.g. TPM3-TRKA)
from functionalization of lit. TRK inhibitor
J. Med. Chem., Oct. 15, 2020
Cullgen Inc., San Diego, CA / Shanghai, CN
CG428 (Cullgen CRBN-based TRK kinase fusion protein degrader)
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year